Semaglutide Research
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes
JAMA Internal Medicine·April 1, 2026
Subodh Verma, Deepak L. Bhatt, et al.
Summary
Oral semaglutide reduced heart failure hospitalization and improved heart failure outcomes in patients with T2D at high cardiovascular risk.
Study Details
Study Design
Post-hoc analysis of SOUL CVOT
Indication
Heart failure outcomes in T2D with ASCVD/CKD
Intervention
Oral semaglutide 14 mg daily
Species
Human